Incyte inaugurates its new production plant in Yverdon

After establishing its European headquarters in Morges in 2020, American biopharmaceutical group Incyte strengthens its presence in the canton of Vaud with the inauguration of a new production site in Yverdon-les-Bains.

Located at the Y-Parc technology park, Incyte‘s new plant consists of a 13,300 square meter campus composed of three buildings. These will house production, technical operations and analytical laboratories.

Announced since 2017, the U.S. group’s new plant will produce biologically active pharmaceutical ingredients for commercial and clinical use. Production will focus on innovative drugs, notably in the fight against cancer.

The new site will be able to accommodate 130 employees specialized in various fields (manufacturing, quality control, engineering, maintenance, etc.).

In Yverdon-les-Bains, Incyte is adding to the 200 or so companies already located in Y-Parc, the largest technology park in Switzerland.

From Delaware to the Health Valley

“Incyte contributes to the creation of high value-added jobs in the heart of the Health Valley and thus further establishes the canton of Vaud as a major innovation hub in the field of life sciences,” stated Philippe Leuba, State Councillor in charge of the economy and innovation.

Based in Delaware, Incyte employs 1,500 people worldwide. The company established its European headquarters in July 2020 in Morges, where 150 people are in charge of clinical development as well as technical and commercial operations.